[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588327":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":39,"locations":46,"responsibleParty":63,"collaborators":44,"id":66,"slug":44,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":44,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":44,"enrollmentInfo":73,"targetDuration":44,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":48,"whyStopped":44,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Khyber Teaching Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Participant Group\u002FArm","PLACEBO_COMPARATOR","Artificial tears Artificial tears 4 times a day",[13],"Drug: Artificial tear",{"label":15,"type":16,"description":17,"interventionNames":18},"Intervention Group\u002FArm","EXPERIMENTAL","Experimental: Insulin Topical insulin 1UI\u002Fml 4 times a day",[19],"Drug: insulin human",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Artificial tear","commercially available artificial tears will be used consisting of same ingredients.",[9],[27],"ARTIFICIAL TEARS",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"insulin human","injection humulin will be used to make topical insulin drops",[15],[33],"HUMULIN INSULIN",[35],{"name":36,"affiliation":37,"role":38},"Shafiq Tanvee, MBBS, FCPS","KHYBER TEACHING HOSPITAL PESHAWAR KPK PAKISTAN","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":44,"email":45},"Shafiq Tanveer, MBBS, FCPS","CONTACT","+923335048601",null,"Shafaq.tan@gmail.com",[47],{"facility":5,"status":48,"city":49,"state":50,"zip":51,"country":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Peshawar","Khyber Pukhtunkhwa","25000","Pakistan",{"type":54,"coordinates":55},"Point",[56,57],71.57849,34.008,{"lat":57,"lon":56},[60],{"name":61,"role":42,"phone":43,"phoneExt":44,"email":62},"shafiq Tanveer, MBBS, FCPS","shafaq.tan@gmail.com",{"type":38,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":44,"oldOrganization":44},"Shafiq Tanveer","Resident Ophthalmologist","100588327",false,"NCT06939959","Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.","Inclusion Criteria:\n\n* Patients having Schirmer's test values of less than 10mm after 5 minutes of the procedure recording plus a non-invasive tear breakup time (TBUT) of less than 10 seconds and the Ocular Surface Disease Index (OSDI) of more than 32 (diagnosed as dry eye disease as per the operational definition of this study).\n* any gender.\n* aged 18 years and above.\n\nExclusion Criteria:\n\n* Patients with active ocular infection, severe ocular surface disease other than Dry eye disease, and those who have undergone ocular surgery within the past 6 months.\n* Under 18 years old","ALL","18 Years",{"count":74,"type":75},126,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to artificial tears in improving the ocular surface interface in patients with dry eye disease over 1 year period.",[81,82],"Dry Eye","Insulin Sensitivity",[84,85,86],"DRY EYE DISEASE","Topical Insulin","Ocular Surface Interface restoration","2025-04-15",{"date":89,"type":90},"2025-04-23","ACTUAL",{"date":92,"type":90},"2025-04-14",{"date":94,"type":75},"2026-04-20",{"name":5,"class":6},1]